Profile data is unavailable for this security.
About the company
Genfit SA is a France-based biopharmaceutical company focused on the discovery and development of therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, particularly due to a lack of approved treatments. The Company provides therapeutic and diagnostic solutions for rare and serious liver diseases , with a particular interest in diseases with largely unmet medical needs. Its laboratory capabilities include pharmacology, molecular and cellular biology, drug candidate screening, medicinal and analytical chemistry, biochemistry, omics analyses, and data science. Its in-house biobank allows to have unparalleled control and precision in the handling and preservation of biological samples, which is crucial to research. The Company leverage artificial intelligence (image processing tools and language models) to create tools that accelerate daily work and decision-making.
- Revenue in EUR (TTM)38.18m
- Net income in EUR-28.89m
- Incorporated1999
- Employees159.00
- LocationGenfit SAParc Eurasante 885 avenue Eugene AvineeLOOS 59120FranceFRA
- Phone+33 320164000
- Fax+33 320164001
- Websitehttps://www.genfit.fr/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Inventiva SA | 17.48m | -110.43m | 98.66m | 112.00 | -- | -- | -- | 5.64 | -2.45 | -2.45 | 0.3854 | -0.6146 | 0.1884 | -- | 9.18 | 156,044.60 | -116.84 | -54.30 | -207.08 | -69.98 | -- | -- | -620.31 | -669.97 | 0.9524 | -19.98 | 6.96 | -- | 43.50 | 40.46 | -103.46 | -- | -0.33 | -- |
Maat Pharma SA | 2.23m | -19.72m | 101.60m | 50.00 | -- | 4.14 | -- | 45.60 | -1.73 | -1.73 | 0.196 | 1.76 | 0.0508 | 4.84 | 4.16 | 44,560.00 | -44.99 | -35.49 | -58.93 | -42.98 | 74.28 | -- | -884.96 | -1,157.54 | 2.76 | -49.61 | 0.4075 | -- | 55.80 | -- | -43.78 | -- | 30.30 | -- |
Eurofins-Cerep SA | 44.07m | 7.64m | 107.94m | 228.00 | 14.13 | 1.67 | 11.23 | 2.45 | 1,514.43 | 1,514.43 | 8,743.94 | 12,820.37 | 0.5864 | 1.67 | 5.08 | 193,287.10 | 10.16 | 14.21 | 12.22 | 17.51 | 85.01 | 73.61 | 17.33 | 19.77 | 4.87 | -- | 0.00005 | -- | -7.47 | 11.60 | -33.72 | 14.64 | -- | -- |
Transgene SA | 7.63m | -22.33m | 135.20m | 158.00 | -- | 6.58 | -- | 17.71 | -0.2227 | -0.2227 | 0.0759 | 0.1553 | 0.1368 | -- | 4.28 | 48,316.46 | -40.00 | -24.81 | -50.27 | -29.79 | -- | -- | -292.48 | -193.24 | -- | -- | 0.4764 | -- | -23.68 | 1.51 | 31.94 | -- | 14.44 | -- |
Cellectis SA | 17.59m | -88.47m | 149.23m | 235.00 | -- | 1.12 | -- | 8.48 | -1.39 | -1.11 | 0.2345 | 1.86 | 0.0619 | -- | 3.86 | 74,861.99 | -31.74 | -24.08 | -46.51 | -30.69 | -- | -64.64 | -513.02 | -308.24 | -- | -6.95 | 0.4142 | -- | -64.26 | -15.57 | -20.55 | -- | -26.15 | -- |
Innate Pharma SA | 24.85m | -34.05m | 165.98m | 168.00 | -- | 5.76 | -- | 6.68 | -0.4215 | -0.4215 | 0.3078 | 0.3557 | 0.1418 | -- | 14.93 | 138,826.80 | -19.43 | -8.83 | -24.80 | -12.11 | 88.00 | 93.17 | -137.03 | -55.55 | -- | -- | 0.7527 | -- | 4.68 | -8.27 | 86.94 | -- | 10.50 | -- |
Ose Immunotherapeutics SA | 2.23m | -23.00m | 167.34m | 55.00 | -- | 7.21 | -- | 75.14 | -1.18 | -1.18 | 0.1138 | 1.06 | 0.0256 | -- | 3.22 | 40,490.91 | -26.46 | -17.17 | -33.15 | -20.55 | -- | -- | -1,032.87 | -94.71 | -- | -55.59 | 0.6659 | -- | -87.83 | -38.07 | -29.52 | -- | -17.11 | -- |
Genfit SA | 38.18m | -28.89m | 195.26m | 159.00 | -- | 2.87 | -- | 5.11 | -0.5814 | -0.5814 | 0.7681 | 1.36 | 0.1961 | 542.00 | 3.52 | 240,100.60 | -14.84 | -12.57 | -18.55 | -15.30 | 94.32 | 94.96 | -75.69 | -76.23 | 2.94 | -7.78 | 0.5080 | -- | 43.70 | 38.49 | -21.82 | -- | -3.27 | -- |
Nanobiotix SA | 36.22m | -33.47m | 218.98m | 102.00 | -- | -- | -- | 6.05 | -0.763 | -0.763 | 0.8429 | -0.4594 | 0.57 | -- | 17.20 | 355,107.80 | -52.68 | -54.11 | -323.15 | -80.68 | -- | -- | -92.42 | -756.15 | -- | -2.42 | 1.87 | -- | -- | 203.88 | 30.40 | -- | -7.81 | -- |
Eurobio Scientific SA | 130.00m | 4.84m | 255.71m | 137.00 | 57.83 | 1.56 | 14.22 | 1.97 | 0.4315 | 0.4315 | 11.59 | 16.02 | 0.4018 | 3.19 | 4.31 | 948,927.00 | 1.49 | 16.91 | 1.80 | 21.53 | 47.11 | 50.95 | 3.72 | 23.34 | 2.32 | 4.03 | 0.3666 | 0.00 | -14.81 | 20.80 | -80.61 | -- | 20.02 | -- |
Sensorion SA | 0.00 | -22.06m | 272.86m | 50.00 | -- | 5.10 | -- | -- | -0.2063 | -0.2063 | 0.00 | 0.1779 | 0.00 | -- | -- | -- | -51.64 | -35.12 | -71.66 | -46.97 | -- | -- | -- | -- | -- | -- | 0.0794 | -- | -- | -- | 4.94 | -- | 126.45 | -- |
Holder | Shares | % Held |
---|---|---|
Tang Capital Management LLCas of 06 Jul 2023 | 2.45m | 4.91% |
Sunny Asset Management SAas of 27 Aug 2024 | 120.00k | 0.24% |
CPR Asset Management SAas of 31 Mar 2024 | 109.11k | 0.22% |
Mandarine Gestion SAas of 29 Feb 2024 | 64.91k | 0.13% |
OFI Invest Asset Management SAas of 29 Aug 2024 | 31.13k | 0.06% |
American Century Investment Management, Inc.as of 05 Sep 2024 | 23.76k | 0.05% |
Dimensional Fund Advisors LPas of 31 May 2024 | 17.55k | 0.04% |
Mercer Global Investments Europe Ltd.as of 30 Jun 2023 | 2.65k | 0.01% |
Lazard Asset Management LLCas of 31 Dec 2023 | 0.00 | 0.00% |
Dimensional Fund Advisors Ltd.as of 30 Jun 2024 | 0.00 | 0.00% |